A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE012 (BRA) · Dr. Kowalski
consented 2023-04-06
Adverse events
Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-05-28 (study day 43); relationship: N
Grade 2 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-07-24 (study day 100); relationship: not assessed
Grade 3 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-08-14 (study day 121); relationship: not assessed
Grade 1 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-11-29 (study day 228); relationship: not assessed
Grade 2 Peripheral neuropathy — outcome: RECOVERED/RESOLVED; onset 2023-12-05 (study day 234); relationship: N
Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-12-14 (study day 243); relationship: not assessed
Grade 1 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-12-25 (study day 254); relationship: not assessed
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2024-01-18 (study day 278); relationship: not assessed
Data queries
No data queries.